Medtronic's Urology Push Gains Momentum With 24-Month Altaviva Data and New Trial Leadership

Medtronic reported 24-month TITAN-2 results for Altaviva, named an ENDURANCE trial investigator, and said AMA granted Category-I CPT codes effective 2028.

Medtronic is steadily assembling the clinical and reimbursement groundwork for its urology franchise, and this week brought a trio of developments that reinforce that effort. The medical device maker unveiled 24-month findings from the exploratory TITAN-2 study of its Altaviva system on Tuesday, pointing to sustained symptom relief in patients treated for nocturia. At the same time, the company named Ariana L. Smith as national principal investigator for the post-approval ENDURANCE trial, a five-year effort that will track 170 patients across as many as 30 U.S. sites to build out the long-term efficacy record for the therapy.

Reimbursement momentum is building alongside the clinical work. Medtronic disclosed on October 1 that the American Medical Association has granted Category-I CPT codes for both Altaviva and its Symplicity Spyral renal denervation system. Those billing codes take effect in January 2028 and should smooth the path toward standardized coverage of the associated procedures.

Vascular Data and Leadership Shuffle

Evidence generation extends well beyond urology. Medtronic presented new prospective, global clinical data from its VenaSeal Spectrum program on October 3, covering the use of the VenaSeal closure system in advanced chronic venous disease. For vascular therapies, such clinical proof is the bedrock for advancing reimbursement discussions and winning over treating physicians. VenaSeal ranks among the established interventional approaches to vein treatment, and ongoing study programs continue to sharpen the definition of where it fits best. In the U.S., commercial and Medicare coverage for the system now reaches 96% of insured individuals.

On the personnel front, Felicia Kurz has stepped into the role of Vice President and General Manager of Cardiac Ablation Solutions, a move confirmed by a company spokesperson as Medtronic sharpens its focus in the heart ablation segment.

Sinus Blades Cleared, MiniMed Separation Takes Shape

The ENT portfolio also advanced, with Medtronic securing 510(k) clearance from the U.S. Food and Drug Administration for its ApexCut EM navigated blades used in sinus surgery — instruments that pair powered cutting with navigation technology. First clinical uses in the U.S. are anticipated later in 2026, following an update to the navigation software.

Meanwhile, the company has locked in the terms of its separation from the MiniMed business. The exchange offer carried a maximum volume of up to 225,361,295 MiniMed shares, with a final exchange ratio of 4.5939 MiniMed shares for each accepted Medtronic share. The offer window ran until October 9.

Shares Close the Week Higher

Investors took the stream of updates in stride. Medtronic stock finished Friday's session at EUR 79.00, a gain of 1.0% on the day, giving the company a market capitalization of roughly EUR 100.18 billion.